VeriMombutyrolactone hamilelikte güvenli mi?
No harmonised reproductive classification (no H360/H361 on ECHA substance listing) and no CIR or SCCS reproductive safety opinion was found for butyrolactone/γ‑butyrolactone; available regulatory and safety documents describe acute toxicity and misuse risk on ingestion but do not identify reproductive teratogenicity from dermal/cosmetic use. Topical exposure could give low but measurable systemic exposure because GBL is a small, water‑miscible molecule that is absorbed and readily metabolised to GHB after systemic uptake, so exposure score is 1 for pregnancy (adult topical). Sources: ECHA substance page; SDSs/regulatory summaries; CDC/FDA reviews of ingestion risks.
Related ingredients
Frequently asked questions
- butyrolactone hamilelikte güvenli mi?
- No harmonised reproductive classification (no H360/H361 on ECHA substance listing) and no CIR or SCCS reproductive safety opinion was found for butyrolactone/γ‑butyrolactone; available regulatory and safety documents describe acute toxicity and misuse risk on ingestion but do not identify reproductive teratogenicity from dermal/cosmetic use. Topical exposure could give low but measurable systemic exposure because GBL is a small, water‑miscible molecule that is absorbed and readily metabolised to GHB after systemic uptake, so exposure score is 1 for pregnancy (adult topical). Sources: ECHA substance page; SDSs/regulatory summaries; CDC/FDA reviews of ingestion risks.
- butyrolactone emzirirken güvenli mi?
- No authoritative reproductive/breastfeeding safety assessment (CIR/SCCS/harmonised CLP) flagging developmental or lactation hazards. Systemic exposure from topical use is expected to be low but measurable in adults; because GBL converts to GHB systemically, breastmilk transfer would only be a concern if significant maternal systemic levels occur (not typical from normal cosmetic topical use). Thus hazard/mechanism remain 0; exposure scored 1 (low but measurable). Sources: ECHA substance information; LactMed/GHB references and FDA/CDC warnings about systemic effects from ingestion rather than topical use.
- butyrolactone bebek cildi için güvenli mi?
- No infant‑specific reproductive/developmental toxicity evidence from authoritative cosmetic safety bodies. Per scoring rules, because adult topical exposure is scored as 1 (measurable), infant skin exposure is increased by +1 (immature barrier and higher SA:BW) to give e=2 (moderate). There is no infant‑specific data showing placental or dermal developmental hazards; the main concern in literature is systemic GHB effects after ingestion/large exposures, not routine topical cosmetic use. Sources: ECHA substance page; EPA/EPA inert reassessment and SDSs describing routes of concern (ingestion/systemic), and EWG ingredient entry.
- VeriMom butyrolactone nasıl puanlıyor?
- VeriMom butyrolactone'yi EU CosIng, ECHA sınıflandırmaları ve PubMed çalışmalarına göre 93/100 (bilinen risk yok) olarak puanlar.
- Hamilelikte butyrolactone yerine neler kullanılabilir?
- Benzer işlevli ve bilinen riski olmayan alternatifleri içeren listemize bakın.
Her etiketi 2 saniyede kontrol et
VeriMom'u ücretsiz indirin — herhangi bir ürünü tarayın ve hamilelik güvenlik puanını anında görün.
Tıbbi Sorumluluk Reddi
Bu bilgiler yalnızca eğitim amaçlıdır ve tıbbi tavsiye niteliği taşımaz. Güvenlik puanları kamuya açık verilere dayanmaktadır ve tüm riskleri yansıtmayabilir. Hamilelik veya emzirme döneminde herhangi bir ürünü kullanmadan önce her zaman sağlık uzmanınıza danışın.